{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:06:55Z","timestamp":1785323215772,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.canrad.2023.07.018","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T21:53:16Z","timestamp":1718315596000},"page":"293-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["La radioth\u00e9rapie du cancer de la prostate augmente-t-elle le risque de seconds cancers\u00a0?"],"prefix":"10.1016","volume":"28","author":[{"given":"A.","family":"Bou\u00e9-Rafl\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Briens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Baty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lafond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Cosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.07.018_bib0435","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.canrad.2021.11.017","article-title":"External radiotherapy for prostatic cancers","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.07.018_bib0440","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.07.018_bib0445","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2009.08.004","article-title":"Dose\u2013volume effects for normal tissues in external radiotherapy: pelvis","volume":"93","author":"Fiorino","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0450","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO;2-W","article-title":"Sarcoma arising in irradiated bone: report of eleven cases","volume":"82","author":"Cahan","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2023.07.018_bib0455","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.otohns.2004.05.012","article-title":"Radiation-induced malignancy of the head and neck","volume":"131","author":"Sale","year":"2004","journal-title":"Otolaryngol-Head Neck Surg"},{"key":"10.1016\/j.canrad.2023.07.018_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/wjon996w","article-title":"Radiation-induced malignancies making radiotherapy a \u201ctwo-edged sword\u201d: a review of literature","volume":"8","author":"Singh","year":"2017","journal-title":"World J Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0465","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2307\/3578892","article-title":"Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958\u20131987","volume":"137","author":"Thompson","year":"1994","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2023.07.018_bib0470","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries","volume":"12","author":"de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0475","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V","article-title":"Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery","volume":"88","author":"Brenner","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2023.07.018_bib0480","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijrobp.2007.12.043","article-title":"Second primary cancer after radiotherapy for prostate cancer\u2014A SEER analysis of brachytherapy versus external beam radiotherapy","volume":"72","author":"Abdel-Wahab","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0485","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/HP.0b013e318285c685","article-title":"Imaging doses and secondary cancer risk from kilovoltage cone-beam CT in radiation therapy","volume":"104","author":"Kim","year":"2013","journal-title":"Health Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0490","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.canrad.2010.07.227","article-title":"Radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9 (RCMI) guid\u00e9e par l\u2019image\u00a0: impact de l\u2019augmentation du volume irradi\u00e9 \u00e0 faible dose\u00a0?","volume":"14","author":"Lisbona","year":"2010","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.07.018_bib0495","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","article-title":"Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial","volume":"102","author":"de Crevoisier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0500","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0360-3016(97)00570-1","article-title":"Is there an increased risk of second primaries following prostate irradiation?","volume":"41","author":"Movsas","year":"1998","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0505","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/j.1464-410X.2012.11385.x","article-title":"Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention","volume":"110","author":"Zelefsky","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.canrad.2023.07.018_bib0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1667\/RR0763.1","article-title":"Solid cancer incidence in atomic bomb survivors: 1958\u20131998","volume":"168","author":"Preston","year":"2007","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2023.07.018_bib0515","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1667\/RR3049","article-title":"Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950\u20131997","volume":"160","author":"Preston","year":"2003","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2023.07.018_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2006.01.027","article-title":"Intensity-modulated radiation therapy, protons, and the risk of second cancers","volume":"65","author":"Hall","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S47220","article-title":"Minimizing second cancer risk following radiotherapy: current perspectives","volume":"7","author":"Ng","year":"2014","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.canrad.2023.07.018_bib0530","first-page":"1","article-title":"Genetic susceptibility to cancer. ICRP publication 79. Approved by the Commission in May 1997. International Commission on Radiological Protection","volume":"28","year":"1998","journal-title":"Ann ICRP"},{"key":"10.1016\/j.canrad.2023.07.018_bib0535","series-title":"Strat\u00e9gie th\u00e9rapeutique dans la maladie de Hodgkin","author":"Somers","year":"1990"},{"key":"10.1016\/j.canrad.2023.07.018_bib0540","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmp.2017.02.015","article-title":"Models for the risk of secondary cancers from radiation therapy","volume":"42","author":"Dasu","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.canrad.2023.07.018_bib0545","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2012.09.001","article-title":"Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship","volume":"86","author":"Berrington de Gonzalez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0550","doi-asserted-by":"crossref","first-page":"13040","DOI":"10.1073\/pnas.0506648102","article-title":"Solid tumor risks after high doses of ionizing radiation","volume":"102","author":"Sachs","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canrad.2023.07.018_bib0555","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.canrad.2016.07.030","article-title":"Pr\u00e9vention des cancers radio-induits","volume":"20","author":"Cosset","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.07.018_bib0560","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/cncr.28769","article-title":"Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study","volume":"120","author":"Davis","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2023.07.018_bib0565","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2014.58.6693","article-title":"No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials","volume":"33","author":"Wiltink","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0570","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02987171","article-title":"Cancer risks after medical radiation","volume":"8","author":"Hall","year":"1991","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"10.1016\/j.canrad.2023.07.018_bib0575","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(99)00279-5","article-title":"Postradiation sarcomas: 20 cases and a literature review","volume":"45","author":"Murray","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0580","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2010.09.012","article-title":"Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer","volume":"98","author":"Huang","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0585","doi-asserted-by":"crossref","first-page":"e2223025","DOI":"10.1001\/jamanetworkopen.2022.23025","article-title":"Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer","volume":"5","author":"Bagshaw","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.canrad.2023.07.018_bib0590","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.urology.2009.02.085","article-title":"Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data","volume":"74","author":"Abdel-Wahab","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2023.07.018_bib0595","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0600","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0605","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.07.018_bib0610","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.urology.2008.07.017","article-title":"Effect of radiation-associated second malignancies on prostate cancer survival","volume":"72","author":"Herr","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2023.07.018_bib0615","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.07.018_bib0620","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ijrobp.2005.11.013","article-title":"Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer","volume":"65","author":"Kendal","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0625","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijrobp.2009.02.011","article-title":"The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients","volume":"76","author":"Bhojani","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0630","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.juro.2008.07.038","article-title":"Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study","volume":"180","author":"Nieder","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0635","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00384-021-04075-6","article-title":"Prostate radiotherapy and the risk of secondary rectal cancer\u00a0\u2013\u00a0a meta-analysis","volume":"37","author":"Nugent","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.canrad.2023.07.018_bib0640","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2009.09.055","article-title":"Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis","volume":"78","author":"Singh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0645","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ijrobp.2014.07.032","article-title":"Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy","volume":"90","author":"Hamilton","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0650","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1055-9965.EPI-09-0241","article-title":"Association of colorectal cancer and prostate cancer and impact of radiation therapy","volume":"18","author":"Huo","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.canrad.2023.07.018_bib0655","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1200\/JCO.2011.35.0991","article-title":"Prostate brachytherapy and second primary cancer risk: a competitive risk analysis","volume":"29","author":"Hinnen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0660","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0167-8140(02)00307-9","article-title":"The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984\u20132000","volume":"65","author":"Pickles","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0665","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.canrad.2023.07.018_bib0670","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","article-title":"Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique","volume":"110","author":"Murray","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0675","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13014-016-0738-z","article-title":"Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis","volume":"12","author":"Hegemann","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0680","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0360-3016(03)00073-7","article-title":"Radiation-induced second cancers: the impact of 3D-CRT and IMRT","volume":"56","author":"Hall","year":"2003","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0685","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ijrobp.2005.03.053","article-title":"The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy","volume":"62","author":"Kry","year":"2005","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0690","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1120\/jacmp.v8i4.2685","article-title":"Monte Carlo determination of radiation-induced cancer risks for prostate patients undergoing intensity-modulated radiation therapy","volume":"8","author":"Stathakis","year":"2007","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0695","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ijrobp.2007.08.046","article-title":"The effect of intensity-modulated radiotherapy on radiation-induced second malignancies","volume":"70","author":"Ruben","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0700","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ijrobp.2011.09.015","article-title":"A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment","volume":"83","author":"Quan","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0705","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jamaoncol.2016.1368","article-title":"Second primary cancers after intensity-modulated vs. 3-dimensional conformal radiation therapy for prostate cancer","volume":"2","author":"Journy","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0710","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijrobp.2011.08.034","article-title":"Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer","volume":"83","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0715","doi-asserted-by":"crossref","first-page":"605119","DOI":"10.3389\/fonc.2020.605119","article-title":"The risk of second primary cancers in prostate cancer survivors treated in the modern radiotherapy era","volume":"10","author":"Jahrei\u00df","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0720","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12885-020-6581-5","article-title":"Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors","volume":"20","author":"Buwenge","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2023.07.018_bib0725","doi-asserted-by":"crossref","first-page":"109659","DOI":"10.1016\/j.radonc.2023.109659","article-title":"Advances in radiotherapy and its impact on second primary cancer risk: a multi-center cohort study in prostate cancer patients","volume":"183","author":"Jahrei\u00df","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0730","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1667\/RR2606.1","article-title":"Out-of-field neutron and leakage photon exposures and the associated risk of second cancers in high-energy photon radiotherapy: current status","volume":"176","author":"Takam","year":"2011","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2023.07.018_bib0735","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1088\/0031-9155\/59\/10\/2457","article-title":"Measurements of the neutron dose equivalent for various radiation qualities, treatment machines and delivery techniques in radiation therapy","volume":"59","author":"H\u00e4lg","year":"2014","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0740","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijrobp.2014.10.040","article-title":"Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors","volume":"91","author":"Berrington de Gonzalez","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0745","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00066-006-1534-8","article-title":"The impact of IMRT and proton radiotherapy on secondary cancer incidence","volume":"182","author":"Schneider","year":"2006","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0750","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.radonc.2008.11.020","article-title":"Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy","volume":"91","author":"Kry","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0755","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2009.12.004","article-title":"Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns","volume":"79","author":"Da\u015fu","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0760","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1088\/0031-9155\/60\/3\/1237","article-title":"Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy","volume":"60","author":"Murray","year":"2015","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0765","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2021.06.023","article-title":"Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques","volume":"161","author":"Dee","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0770","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.canrad.2021.11.019","article-title":"Prostate cancer brachytherapy: SFRO guidelines 2021","volume":"26","author":"Pommier","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.07.018_bib0775","first-page":"iii","article-title":"Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98","volume":"35","year":"2005","journal-title":"Ann ICRP"},{"key":"10.1016\/j.canrad.2023.07.018_bib0780","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/pros.24362","article-title":"Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy","volume":"82","author":"Cho","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.canrad.2023.07.018_bib0785","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0790","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2007.08.080","article-title":"Quality assurance needs for modern image-based radiotherapy: recommendations from 2007 interorganizational symposium on \u201cQuality Assurance of Radiation Therapy: Challenges of Advanced Technology.\u201d","volume":"71","author":"Williamson","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0795","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canrad.2021.08.002","article-title":"Image-guided radiotherapy","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.07.018_bib0800","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.phro.2022.02.004","article-title":"Monte Carlo-based software for 3D personalized dose calculations in image-guided radiotherapy","volume":"21","author":"Le Deroff","year":"2022","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0805","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.canrad.2020.05.023","article-title":"Gestion des doses li\u00e9es \u00e0 l\u2019imagerie de positionnement en radioth\u00e9rapie","volume":"25","author":"Delpon","year":"2021","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.07.018_bib0810","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1118\/1.2815625","article-title":"Evaluation of the effect of patient dose from cone beam computed tomography on prostate IMRT using Monte Carlo simulation","volume":"35","author":"Chow","year":"2008","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2023.07.018_bib0815","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0820","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejmp.2015.07.147","article-title":"Ultrasound versus cone-beam CT image-guided radiotherapy for prostate and post-prostatectomy pretreatment localization","volume":"31","author":"Fargier-Voiron","year":"2015","journal-title":"Phys Med"},{"key":"10.1016\/j.canrad.2023.07.018_bib0825","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/(SICI)1097-0045(19971001)33:2<75::AID-PROS1>3.0.CO;2-L","article-title":"Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study","volume":"33","author":"Pawlish","year":"1997","journal-title":"Prostate"},{"key":"10.1016\/j.canrad.2023.07.018_bib0830","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.juro.2013.02.1719","article-title":"333 second cancers following radiotherapy in prostate cancer patients in the prostate, lung, colorectal and ovarian (plco) cancer screening trial","volume":"189","author":"Black","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0835","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2017.01.009","article-title":"Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer","volume":"123","author":"Wang","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0840","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/0284186X.2019.1581377","article-title":"Second cancers in radically treated Norwegian prostate cancer patients","volume":"58","author":"Aksness\u00e6ther","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0845","doi-asserted-by":"crossref","first-page":"771956","DOI":"10.3389\/fonc.2021.771956","article-title":"Impact of advanced radiotherapy on second primary cancer risk in prostate cancer survivors: a nationwide cohort study","volume":"11","author":"Jahrei\u00df","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.07.018_bib0850","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.gastro.2004.12.038","article-title":"Increased risk of rectal cancer after prostate radiation: a population-based study","volume":"128","author":"Baxter","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canrad.2023.07.018_bib0855","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cncr.22083","article-title":"Cancer incidence after localized therapy for prostate cancer","volume":"107","author":"Moon","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2023.07.018_bib0430","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:44:32Z","timestamp":1719715472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1278321824000544"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.07.018","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La radioth\u00e9rapie du cancer de la prostate augmente-t-elle le risque de seconds cancers\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}